Dr. Balar highlights promising evidence on the potential benefits of the use of immunotherapy in the advanced bladder cancer setting.
Arjun V. Balar, MD
Advertisement
Articles by Arjun V. Balar, MD
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
Advertisement
Latest Updated Articles
First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial CancerPublished: June 14th 2016 | Updated:
Recent Clinical Trials Explore Immunotherapies for Urothelial CarcinomaPublished: April 15th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
2
ASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC
3
TUB-040 Elicits Early Responses in Platinum-Resistant Ovarian Cancer
4
PAM Inhibition Adds Value in HR+/HER2- PIK3CA Wild Type Advanced Breast Cancer
5
